Abstract
Alzheimer’s disease (AD) is a progressive degenerative disorder of the brain and is the most common form of dementia. To-date no simple, inexpensive and minimally invasive procedure is available to confirm with certainty the early diagnosis of AD prior to the manifestations of symptoms characteristic of the disease. Therefore, if population screening of individuals is to be performed, more suitable, easily accessible tissues would need to be used for a diagnostic test that would identify those who exhibit cellular pathology indicative of mild cognitive impairment (MCI) and AD risk so that they can be prioritized for primary prevention. This need for minimally invasive tests could be achieved by targeting surrogate tissues, since it is now well recognized that AD is not only a disorder restricted to pathology and biomarkers within the brain. Human buccal cells for instance are accessible in a minimally invasive manner, and exhibit cytological and nuclear morphologies that may be indicative of accelerated ageing or neurodegenerative disorders such as AD. However, to our knowledge there is no review available in the literature covering the biology of buccal cells and their applications in AD biomarker research. Therefore, the aim of this review is to summarize some of the main findings of biomarkers reported for AD in peripheral tissues, with a further focus on the rationale for the use of the buccal mucosa (BM) for biomarkers of AD and the evidence to date of changes exhibited in buccal cells with AD.
Keywords: Alzheimer’s disease, buccal mucosa, diagnosis, mild cognitive impairment, peripheral biomarkers.
Current Alzheimer Research
Title:Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells
Volume: 11 Issue: 6
Author(s): Maxime Francois, Wayne Leifert, Ralph Martins, Philip Thomas and Michael Fenech
Affiliation:
Keywords: Alzheimer’s disease, buccal mucosa, diagnosis, mild cognitive impairment, peripheral biomarkers.
Abstract: Alzheimer’s disease (AD) is a progressive degenerative disorder of the brain and is the most common form of dementia. To-date no simple, inexpensive and minimally invasive procedure is available to confirm with certainty the early diagnosis of AD prior to the manifestations of symptoms characteristic of the disease. Therefore, if population screening of individuals is to be performed, more suitable, easily accessible tissues would need to be used for a diagnostic test that would identify those who exhibit cellular pathology indicative of mild cognitive impairment (MCI) and AD risk so that they can be prioritized for primary prevention. This need for minimally invasive tests could be achieved by targeting surrogate tissues, since it is now well recognized that AD is not only a disorder restricted to pathology and biomarkers within the brain. Human buccal cells for instance are accessible in a minimally invasive manner, and exhibit cytological and nuclear morphologies that may be indicative of accelerated ageing or neurodegenerative disorders such as AD. However, to our knowledge there is no review available in the literature covering the biology of buccal cells and their applications in AD biomarker research. Therefore, the aim of this review is to summarize some of the main findings of biomarkers reported for AD in peripheral tissues, with a further focus on the rationale for the use of the buccal mucosa (BM) for biomarkers of AD and the evidence to date of changes exhibited in buccal cells with AD.
Export Options
About this article
Cite this article as:
Francois Maxime, Leifert Wayne, Martins Ralph, Thomas Philip and Fenech Michael, Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells, Current Alzheimer Research 2014; 11 (6) . https://dx.doi.org/10.2174/1567205011666140618103827
DOI https://dx.doi.org/10.2174/1567205011666140618103827 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Executive Dyscontrol in Dementia, with Emphasis on Subcortical Pathology and the Role of Butyrylcholinesterase
Current Alzheimer Research The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research The Endocannabinoid System and Huntingtons Disease
Current Drug Targets - CNS & Neurological Disorders Patented In Vitro Blood-Brain Barrier Models in CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Non-Ceruloplasmin Copper Distinguishes A Distinct Subtype of Alzheimer’s Disease: A Study of EEG-Derived Brain Activity
Current Alzheimer Research Anandamide Dysfunction in Prodromal and Established Psychosis
Current Pharmaceutical Design Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology An Exposition of <sup>11</sup>C and <sup>18</sup>F Radiotracers Synthesis for PET Imaging
Current Radiopharmaceuticals Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders
Current Alzheimer Research Subject Index to Volume 1
Medicinal Chemistry Reviews - Online (Discontinued) Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies
Current Topics in Medicinal Chemistry Drugs for Targeted Therapies of Alzheimer’s Disease
Current Medicinal Chemistry Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design Granulocyte Colony-Stimulating Factor Attenuates Blood-Brain Barrier Damage and Improves Cognitive Function in Spontaneously Hypertensive Rats
CNS & Neurological Disorders - Drug Targets Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research